Description

Goserelin acts as a peptide agonist at the gonadotropin-releasing hormone (GnRH) or luteinizing hormone releasing hormone (LHRH) receptor, stimulating release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and decreasing androgen levels. Goserelin exhibits anticancer chemotherapeutic benefit, inhibiting cell proliferation and tumor growth in cellular and animal models of prostate cancer, likely through indirect activation of PKC and inhibition of EGFR activity. Goserelin also inhibits cell proliferation and tumor growth in cellular and animal models of ovarian cancer through a mechanism that involves inhibition of Akt phosphorylation. In other animal models, goserelin increases bone elongation.